Phase lb combination trial of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with locally advanced or metastatic solid tumors

被引：0
|
作者：
Infante, Jeffrey R.
Gandhi, Leena
Shapiro, Geoffrey
Burris, Howard A.
Bendell, Johanna C.
Baselga, Jose
Hsu, Karl
Faivre, Thea
Asatiani, Ekatherine
Heist, Rebecca Suk
机构：
[1] Sarah Cannon Res Inst, Nashville, TN USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
[4] Sanofi, Cambridge, MA USA
[5] Merck Serono SA, Geneva, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3118
引用
收藏
页数：1
相关论文
共 50 条
  • [41] POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS OF THE DUAL PI3K/MTOR INHIBITOR GDC-0980 IN PHASE I PATIENTS WITH ADVANCED SOLID TUMORS
    Jin, J. Y.
    Ware, J.
    Malhi, V.
    Upadhyay, S.
    Wu, J.
    Yan, Y.
    Lauchle, J.
    Holden, S.
    Derynck, M.
    Dresser, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 89 : S81 - S81
  • [42] Population pharmacokinetics of PQR309, a dual PI3K/mTOR inhibitor in adult patients with advanced solid tumors
    Machacek, Matthias
    Renaud, Lionel
    Dimitrijevic, Sasa
    Schmitz, Debora
    Ivanova, Elena
    Jorga, Karin
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
    Toshihiko Doi
    Nozomu Fuse
    Takayuki Yoshino
    Takashi Kojima
    Hideaki Bando
    Hideaki Miyamoto
    Masato Kaneko
    Motonobu Osada
    Atsushi Ohtsu
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 89 - 98
  • [44] A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors
    Faulkner, Neil
    LoRusso, Patricia M.
    Guthrie, Tina
    Soria, Jean-Charles
    Bahleda, Ratislav
    Bendell, Johanna C.
    Infante, Jeffrey R.
    Massard, Christophe
    Van Leeuwen, Barbara
    Martini, Jean-Francois
    Scheffold, Christian
    Burns, Howard A.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [45] A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
    Doi, Toshihiko
    Fuse, Nozomu
    Yoshino, Takayuki
    Kojima, Takashi
    Bando, Hideaki
    Miyamoto, Hideaki
    Kaneko, Masato
    Osada, Motonobu
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 89 - 98
  • [46] Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Edelman, Gerald
    Rodon, Jordi
    Lager, Joanne
    Castell, Christelle
    Jiang, Jason
    Van Allen, Eliezer M.
    Wagle, Nikhil
    Lindeman, Neal I.
    Sholl, Lynette M.
    Shapiro, Geoffrey I.
    ONCOLOGIST, 2018, 23 (04): : 401 - +
  • [47] The PI3K/mTOR inhibitor BEZ235 given twice daily for the treatment of patients (pts) with advanced solid tumors
    Arkenau, Hendrik-Tobias
    Jones, Suzanne Fields
    Kurkjian, Carla
    Infante, Jeffrey R.
    Pant, Shubham
    Burris, Howard A.
    Moore, Kathleen N.
    McMeekin, D. Scott
    Greco, Frank A.
    Ramsey, Sara
    Bendell, Johanna C.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] A phase I basket study of the PI3K inhibitor taselisib (GDC-0032) in PIK3CA-mutated locally advanced or metastatic solid tumors
    Jhaveri, Komal
    Juric, Dejan
    Saura, Cristina
    Cervantes, Andres
    Melnyk, Anton
    Patel, Manish R.
    Oliveira, Mafalda
    Gambardella, Valentina
    Ribrag, Vincent
    Ma, Cynthia X.
    Aljumaily, Raid
    Bedard, Philippe L.
    Sachdev, Jasgit C.
    Bond, John
    Jones, Surai
    Wilson, Timothy R.
    Wei, Michael C.
    Baselga, Jose
    CANCER RESEARCH, 2018, 78 (13)
  • [49] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Wilson, Timothy R.
    Ware, Joseph A.
    Bohorquez, Sandra M. Sanabria
    Savage, Heidi M.
    Sampath, Deepak
    Salphati, Laurent
    Lin, Ray S.
    Jin, Huan
    Parmar, Hema
    Hsu, Jerry Y.
    Von Hoff, Daniel D.
    Baselga, Jose
    CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
  • [50] Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer (vol 15, pg 163, 2020)
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Eskens, Ferry
    Blumenschein, George, Jr.
    Richards, Donald
    Genvresse, Isabelle
    Reschke, Susanne
    Granvil, Camille
    Skubala, Adam
    Pena, Carol
    Mross, Klaus
    TARGETED ONCOLOGY, 2020, 15 (06) : 803 - 803
12345